Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of alzheimer disease

Yinxing Liu; Christa Studzinski; Tina Beckett; Hanjun Guan; Matthew A. Hersh; M. Paul Murphy; Ronald Klein; Louis B. Hersh

doi:10.1038/mt.2009.115

Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of alzheimer disease

Yinxing Liu, Christa Studzinski, Tina Beckett, Hanjun Guan, Matthew A. Hersh, M. Paul Murphy, Ronald Klein, Louis B. Hersh

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

Neprilysin (NEP) is a zinc metallopeptidase that efficiently degrades the amyloid β(A β) peptides believed to be involved in the etiology of Alzheimer disease (AD). The focus of this study was to develop a new and tractable therapeutic approach for treating AD using NEP gene therapy. We have introduced adeno-associated virus (AAV) expressing the mouse NEP gene into the hindlimb muscle of 6-month-old human amyloid precursor protein (hAPP) (3X-Tg-AD) mice, an age which correlates with early stage AD. Overexpression of NEP in muscle decreased brain soluble A β peptide levels by ˜60% and decreased amyloid deposits by ˜50%, with no apparent adverse effects. Expression of NEP on muscle did not affect the levels of a number of other physiological peptides known to be in vitro substrates. These findings demonstrate that peripheral expression of NEP and likely other peptidases represents an alternative to direct administration into brain and illustrates the potential for using NEP expression in muscle for the prevention and treatment of AD.

Original language	English
Pages (from-to)	1381-1386
Number of pages	6
Journal	Molecular Therapy
Volume	17
Issue number	8
DOIs	https://doi.org/10.1038/mt.2009.115
State	Published - Aug 2009

Bibliographical note

Funding Information:
This study was supported by NIH grants DA 02243 from the National Institute on Drug Abuse, AG 24899 from the National Institute on Aging, and P20RR02017 from the National Center for Research Resources (NCRR). We thank Hansruedi Beuler for suggesting the use of muscle as a site for NEP expression. The University of Kentucky has filed a patent application based in part on these studies.

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/mt.2009.115

Cite this

@article{42939061d41f4bbaa79c2ea92bd95a1b,

title = "Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of alzheimer disease",

abstract = "Neprilysin (NEP) is a zinc metallopeptidase that efficiently degrades the amyloid β(A β) peptides believed to be involved in the etiology of Alzheimer disease (AD). The focus of this study was to develop a new and tractable therapeutic approach for treating AD using NEP gene therapy. We have introduced adeno-associated virus (AAV) expressing the mouse NEP gene into the hindlimb muscle of 6-month-old human amyloid precursor protein (hAPP) (3X-Tg-AD) mice, an age which correlates with early stage AD. Overexpression of NEP in muscle decreased brain soluble A β peptide levels by ˜60% and decreased amyloid deposits by ˜50%, with no apparent adverse effects. Expression of NEP on muscle did not affect the levels of a number of other physiological peptides known to be in vitro substrates. These findings demonstrate that peripheral expression of NEP and likely other peptidases represents an alternative to direct administration into brain and illustrates the potential for using NEP expression in muscle for the prevention and treatment of AD.",

author = "Yinxing Liu and Christa Studzinski and Tina Beckett and Hanjun Guan and Hersh, {Matthew A.} and Murphy, {M. Paul} and Ronald Klein and Hersh, {Louis B.}",

note = "Funding Information: This study was supported by NIH grants DA 02243 from the National Institute on Drug Abuse, AG 24899 from the National Institute on Aging, and P20RR02017 from the National Center for Research Resources (NCRR). We thank Hansruedi Beuler for suggesting the use of muscle as a site for NEP expression. The University of Kentucky has filed a patent application based in part on these studies.",

year = "2009",

month = aug,

doi = "10.1038/mt.2009.115",

language = "English",

volume = "17",

pages = "1381--1386",

number = "8",

}

TY - JOUR

T1 - Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of alzheimer disease

AU - Liu, Yinxing

AU - Studzinski, Christa

AU - Beckett, Tina

AU - Guan, Hanjun

AU - Hersh, Matthew A.

AU - Murphy, M. Paul

AU - Klein, Ronald

AU - Hersh, Louis B.

N1 - Funding Information: This study was supported by NIH grants DA 02243 from the National Institute on Drug Abuse, AG 24899 from the National Institute on Aging, and P20RR02017 from the National Center for Research Resources (NCRR). We thank Hansruedi Beuler for suggesting the use of muscle as a site for NEP expression. The University of Kentucky has filed a patent application based in part on these studies.

PY - 2009/8

Y1 - 2009/8

N2 - Neprilysin (NEP) is a zinc metallopeptidase that efficiently degrades the amyloid β(A β) peptides believed to be involved in the etiology of Alzheimer disease (AD). The focus of this study was to develop a new and tractable therapeutic approach for treating AD using NEP gene therapy. We have introduced adeno-associated virus (AAV) expressing the mouse NEP gene into the hindlimb muscle of 6-month-old human amyloid precursor protein (hAPP) (3X-Tg-AD) mice, an age which correlates with early stage AD. Overexpression of NEP in muscle decreased brain soluble A β peptide levels by ˜60% and decreased amyloid deposits by ˜50%, with no apparent adverse effects. Expression of NEP on muscle did not affect the levels of a number of other physiological peptides known to be in vitro substrates. These findings demonstrate that peripheral expression of NEP and likely other peptidases represents an alternative to direct administration into brain and illustrates the potential for using NEP expression in muscle for the prevention and treatment of AD.

AB - Neprilysin (NEP) is a zinc metallopeptidase that efficiently degrades the amyloid β(A β) peptides believed to be involved in the etiology of Alzheimer disease (AD). The focus of this study was to develop a new and tractable therapeutic approach for treating AD using NEP gene therapy. We have introduced adeno-associated virus (AAV) expressing the mouse NEP gene into the hindlimb muscle of 6-month-old human amyloid precursor protein (hAPP) (3X-Tg-AD) mice, an age which correlates with early stage AD. Overexpression of NEP in muscle decreased brain soluble A β peptide levels by ˜60% and decreased amyloid deposits by ˜50%, with no apparent adverse effects. Expression of NEP on muscle did not affect the levels of a number of other physiological peptides known to be in vitro substrates. These findings demonstrate that peripheral expression of NEP and likely other peptidases represents an alternative to direct administration into brain and illustrates the potential for using NEP expression in muscle for the prevention and treatment of AD.

UR - http://www.scopus.com/inward/record.url?scp=70350728321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350728321&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.115

DO - 10.1038/mt.2009.115

M3 - Article

C2 - 19471248

AN - SCOPUS:70350728321

VL - 17

SP - 1381

EP - 1386

IS - 8

ER -

Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of alzheimer disease

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this